Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Canadian study monitors Venetoclax's Real-World impact on AML

NCT ID NCT05424562

Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how well the drug venetoclax works for adults with acute myeloid leukemia (AML) who cannot handle strong chemotherapy. About 210 people across Canada will take venetoclax pills daily as part of their normal care. Researchers will track their overall survival and remission rates for up to 36 months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

210 people

The number who actually took part.

Started

Sep 2022

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult participants with acute myeloid leukemia (AML) treated with venetoclax per approved local label in Canada.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of Acute Myeloid Leukemia (AML). * Ineligible for intensive chemotherapy, determined by the physician's assessment of age, Eastern Cooperative Oncology Group Performance Status (ECOG-PS), comorbidities, regional guidelines, and institutional practice. * Participant for whom the physician has decided to initiate venetoclax treatment in accordance with the local label. The decision to treat with venetoclax is made by the physician prior to any decision to approach the participant to participate in this study. Exclusion Criteria: \- Participation in an interventional clinical trial within 30 days prior to venetoclax treatment initiation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute myeloid leukemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute myeloid leukemia

Contacts and locations

Locations

  • Allan Blair Cancer Centre /ID# 247663

    Regina, Saskatchewan, S4T 7T1, Canada

  • BC Cancer - Surrey /ID# 257515

    Surrey, British Columbia, V3V 1Z2, Canada

  • BC Cancer - Victoria /ID# 257339

    Victoria, British Columbia, V8R 6V5, Canada

  • CIUSSS de l'Estrie - CHUS /ID# 248915

    Sherbrooke, Quebec, J1G 2E8, Canada

  • CancerCare Manitoba /ID# 246414

    Winnipeg, Manitoba, R3E 0V9, Canada

  • Disc_Royal Victoria Hospital / McGill University Health Centre /ID# 249704

    Montreal, Quebec, H4A 3J1, Canada

  • Eastern Regional Health Authority /ID# 250241

    St. John's, Newfoundland and Labrador, A1B 3V6, Canada

  • Juravinski Cancer Centre /ID# 247183

    Hamilton, Ontario, L8V 1C3, Canada

  • Kingston Health Sciences Centre /ID# 253439

    Kingston, Ontario, K7L 2V7, Canada

  • Lakeridge Health - Oshawa /ID# 246412

    Oshawa, Ontario, L1G 2B9, Canada

  • London Health Sciences Center- University Hospital /ID# 248027

    London, Ontario, N6A 5W9, Canada

  • Queen Elizabeth II Health Sciences Centre - Victoria General /ID# 246514

    Halifax, Nova Scotia, B3H 2Y9, Canada

  • Saskatoon Cancer Centre /ID# 247181

    Saskatoon, Saskatchewan, S7N 4H4, Canada

  • Sunnybrook Health Sciences Centre /ID# 251966

    Toronto, Ontario, M4N 3M5, Canada

  • The Moncton Hospital /ID# 247277

    Moncton, New Brunswick, E1C 6Z8, Canada

  • Thunder Bay Regional Research Institute /ID# 249163

    Thunder Bay, Ontario, P7B 6V4, Canada

  • Tom Baker Cancer Centre /ID# 248113

    Calgary, Alberta, T2N 4N2, Canada

  • University Health Network_Princess Margaret Cancer Centre /ID# 249607

    Toronto, Ontario, M5G 2M9, Canada

  • University of Alberta Hospital /ID# 251531

    Edmonton, Alberta, T6G 2B7, Canada

  • Vancouver General Hospital /ID# 245438

    Vancouver, British Columbia, V5Z 1M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.